Company intelligence / Profile preview

FSC Holdings

Charlotte, North Carolina, United States

Ownership: Private
Employees: ~45
Development stage: Other

Overview

Prior to acquisition, FSC marketed three commercial prescription pediatric pharmaceuticals (rabeprazole sodium, carbinoxamine maleate, cefaclor) and a cleared pediatric medical device (Flexichamber) in the US. These products addressed infection, allergy, GERD, and improved administration of inhaled medications. All products had established regulatory approvals or clearances.

Therapeutic areas: Infectious DiseasesImmunologyPulmonologyGastroenterology
Modalities: Small moleculeMedical device
Industry: Biotech

Partnerships

Eisai Inc. (for AcipHex Sprinkle distribution)Tris Pharma (for Karbinal ER exclusive license)

Beyond the preview

Go deeper on FSC Holdings.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FSC Holdings.

Explore the full profile